<code id='723DE3969C'></code><style id='723DE3969C'></style>
    • <acronym id='723DE3969C'></acronym>
      <center id='723DE3969C'><center id='723DE3969C'><tfoot id='723DE3969C'></tfoot></center><abbr id='723DE3969C'><dir id='723DE3969C'><tfoot id='723DE3969C'></tfoot><noframes id='723DE3969C'>

    • <optgroup id='723DE3969C'><strike id='723DE3969C'><sup id='723DE3969C'></sup></strike><code id='723DE3969C'></code></optgroup>
        1. <b id='723DE3969C'><label id='723DE3969C'><select id='723DE3969C'><dt id='723DE3969C'><span id='723DE3969C'></span></dt></select></label></b><u id='723DE3969C'></u>
          <i id='723DE3969C'><strike id='723DE3969C'><tt id='723DE3969C'><pre id='723DE3969C'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:96
          Johnson & Johnson logo. -- health coverage from STAT.
          Chris O'Meara/AP

          Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

          Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

          advertisement

          In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          6 solutions to address cancer drug shortages and others
          6 solutions to address cancer drug shortages and others

          GeorgeFrey/GettyImagesWASHINGTON—RepublicansandDemocratsalikewanttostopdrugshortagesfromhappening.Th

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

          DarronCummings/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne